Working… Menu
Trial record 22 of 66 for:    strength | ( Map: India )

Stem Cell Therapy in Incurable Neurological Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02245776
Recruitment Status : Withdrawn
First Posted : September 22, 2014
Last Update Posted : October 25, 2018
Information provided by (Responsible Party):
Neurogen Brain and Spine Institute

Brief Summary:
The purpose of the study was to analyze the benefit of autologous mononuclear cell therapy in incurable neurological disorders.

Condition or disease Intervention/treatment Phase
Neurological; Disorder, Nervous System Biological: Stem Cell Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Autologous Bone Marrow Mononuclear Cell Therapy for Incurable Neurological Disorders
Study Start Date : December 2008
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Stem Cell
Bone marrow mononuclear cell transplantation
Biological: Stem Cell
Intrathecal autologous bone marrow mononuclear cell transplantation

Primary Outcome Measures :
  1. Change in various clinical symptoms of neurological disorders [ Time Frame: 1 year ]
    Change in various symptoms such as muscle strength, limb strength, ambulation, neck holding, bladder bowel management, spasticity, sensation, speech, etc depending on the disorder will be recorded at 1 year follow up. Percentage analysis of each symptom will be carried out to study the benefits of stem cell therapy on them.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosed cases of incurable neurological disorders
  • age above 6 months

Exclusion Criteria:

  • presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
  • malignancies
  • bleeding tendencies
  • pneumonia
  • renal failure
  • severe liver dysfunction
  • severe anemia [Hemoglobin < 8]
  • any bone marrow disorder
  • space occupying lesion in brain
  • other acute medical conditions such as respiratory infection and pyrexia
  • pregnancy
  • lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02245776

Layout table for location information
Neurogen brain and spine institute
Navi Mumbai, Maharashtra, India, 400706
Sponsors and Collaborators
Neurogen Brain and Spine Institute

Layout table for additonal information
Responsible Party: Neurogen Brain and Spine Institute Identifier: NCT02245776     History of Changes
Other Study ID Numbers: NGBSI-16
First Posted: September 22, 2014    Key Record Dates
Last Update Posted: October 25, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Neurogen Brain and Spine Institute:
Incurable Neurological Disorders
Autologous mononuclear cell therapy
Stem cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Diseases
Pathologic Processes